Epilepsy

24 treatments and conditions followed through the public trial records. Not medical advice.How a status is set

Lists this condition and the narrower ones beneath it. A condition is not a diagnosis.

Treatments and conditions

Epilepsy
Treatment and conditionWhere it standsTrials
30mg PRAX-628 for epilepsy, generalizedPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Bexicaserin for epilepsies, myoclonicPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Brivaracetam for epilepsy, absencePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cannabidiol for drug resistant epilepsyPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cannabidiol for epilepsies, myoclonicPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)10
Cannabidiol for epilepsyPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)3
Cannabidiol for epilepsy, absenceTrials ended early, as of 19 Nov 2026 (not yet checked by a person)2
Cannabidiol for lennox gastaut syndromePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)10
Cannabidiol for spasms, infantilePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)3
Cenobamate (syrup) for 2 to < 18 year olds + Cenobamate (tablet) for 12 to < 18 year olds for epilepsies, partialPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Device: Directional Deep Brain Stimulation for epilepsyTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Erenumab for epilepsyPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
ETX101 for epilepsies, myoclonicPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)2
Exogenous ketone ester for drug resistant epilepsyPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ION337 for epilepsies, myoclonicPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
JZP926 capsule for myoclonic epilepsy, juvenilePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
lentiviral gene therapy for drug resistant epilepsyTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Lifus for epilepsyTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Opakalim for drug resistant epilepsyPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
Opakalim for epilepsies, partialPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
RAP-219 for epilepsies, partialPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Relutrigine for spasms, infantilePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
STK-001 - Single Ascending Doses for epilepsies, myoclonicPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Zorevunersen for epilepsies, myoclonicPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)3